Earnings Calls Videos
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Earnings Calls Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Earnings CallsVideosLupin Q3 Profit Jumps 37%! Is $1 Billion US Sales Next? | Margin Outlook & GLP-1 Big Bet | ET Now
Asia StocksEarnings CallsBioTech

Lupin Q3 Profit Jumps 37%! Is $1 Billion US Sales Next? | Margin Outlook & GLP-1 Big Bet | ET Now

•February 13, 2026
0
ET Now
ET Now•Feb 13, 2026

Original Description

Lupin Limited reports a strong quarter with profit up 37% to ₹1,175.5 crore. CEO Vinita Gupta, MD Nilesh Gupta, and CFO Ramesh Swaminathan discuss $1 billion US sales trajectory, EBITDA margin outlook, Mirabegron settlement clarity, GLP-1 plans including semaglutide launch, biosimilars pipeline, and growth in India formulations. Is Lupin set for sustained earnings momentum?
#etnow #lupin #q3results #lupinshare #q3earnings #pharmasector #businessnews #budget2026withetnow #stockmarket
YouTube Channel - https://www.youtube.com/@ETNow
Subscribe To ET Now For Latest Updates On Stocks Market News , Business News, Company News, IPO & More | https://bit.ly/SubscribeToETNow
Subscribe Now To Our Network Channels :-
ET Now Swadesh: https://www.youtube.com/etnowswadesh
Times Now: http://goo.gl/U9ibPb
Social Media Links :-
Twitter - http://goo.gl/hA0vDt
Facebook - http://goo.gl/5Lr4mC
Website - https://www.etnownews.com
Follow us on Google News for latest updates
ET Now: https://news.google.com/publications/CAAqBwgKMK3HxQsw0OLcAw?hl=en-IN&gl=IN&ceid=IN%3Aen
Times Now Navbharat: https://bit.ly/3zDaKJo
Times Now : https://bit.ly/3CyrrYg
Zoom: https://bit.ly/3CEK0dv
0

Comments

Want to join the conversation?

Loading comments...